ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $36.50.

Separately, Laidlaw initiated coverage on ABIVAX Société Anonyme in a report on Monday, July 29th. They set a “buy” rating and a $48.00 price target on the stock.

ABIVAX Société Anonyme Stock Performance

NASDAQ:ABVX opened at $11.60 on Friday. The stock’s fifty day moving average is $11.65 and its 200 day moving average is $13.26. ABIVAX Société Anonyme has a fifty-two week low of $7.99 and a fifty-two week high of $17.02. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.08 and a current ratio of 3.04.

Institutional Trading of ABIVAX Société Anonyme

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in ABIVAX Société Anonyme in the 1st quarter worth about $81,000. Capstone Investment Advisors LLC purchased a new position in ABIVAX Société Anonyme in the 4th quarter worth about $618,000. Ghisallo Capital Management LLC purchased a new position in ABIVAX Société Anonyme in the 4th quarter worth about $642,000. Kennedy Capital Management LLC increased its stake in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares during the period. Finally, Rosalind Advisors Inc. purchased a new position in ABIVAX Société Anonyme in the 1st quarter worth about $5,411,000. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.